Forest Laboratories, Inc. to Present Cariprazine Results from a Phase 3 Trial & Two Pharmacology Studies at the American Coll...
December 03 2012 - 5:18PM
Business Wire
Forest Laboratories, Inc. (NYSE: FRX) today announced it will be
presenting data on cariprazine at the American College of
Neuropsychopharmacology Annual Meeting scheduled December 2-6, 2012
in Hollywood, FL. Forest Laboratories, Inc recently submitted a New
Drug Application to the U.S. Food and Drug Administration (FDA) for
cariprazine for the treatment of schizophrenia and the acute
treatment of manic or mixed episodes associated with Bipolar I
disorder.
The cariprazine results will be announced in 3 poster
presentations:
- Efficacy and Safety of Cariprazine in
Acute Exacerbation of Schizophrenia: A Phase III, International,
Randomized, Double-blind, Placebo-controlled Trial (Poster 9:
Wednesday, December 5 from 5:30 pm - 7:30 pm EST)
- Cariprazine Exhibits Dopamine D3
Receptor-Dependent Antidepressant-Like Activity in the Chronic
Unpredictable Stress Model of Anhedonia (Poster 12: Monday,
December 3 from 5:30 pm - 7:30 pm EST)
- Effects of Chronic Cariprazine
Administration on Serotonin and Glutamate Receptor Subtypes (Poster
161: Monday, December 3 from 5:30 pm - 7:30 pm EST)
About Cariprazine
Cariprazine is an orally active and potent dopamine
D3-preferring D3 /D2 receptor partial agonist. Cariprazine has a
low affinity at other receptor sites such as 5-HT2C, muscarinic,
and adrenergic which have been associated with adverse events.
Cariprazine was discovered by Gedeon Richter Plc and is licensed
to Forest Laboratories Inc., in the U.S. and Canada.
About Gedeon Richter Plc.
Gedeon Richter Plc. (www.richter.hu) headquartered in
Budapest/Hungary, is a major pharmaceutical company in Central
Eastern Europe, with an expanding direct presence in Western
Europe. Richter’s consolidated sales were approximately EUR
1.1 billion (USD 1.5 billion) while its market capitalization
amounted to EUR 2.1 billion (USD 2.7 billion) in 2011. The product
portfolio of the Company covers almost all important therapeutic
areas, including gynecology, central nervous system and
cardiovascular. Having the largest R&D unit in Central Eastern
Europe, the Company’s original research activity focuses on CNS
disorders. With its widely acknowledged steroid chemistry expertise
Richter is a significant player in the female healthcare field
worldwide. Richter is also active in the scope of biosimilar
product development.
About Forest Laboratories
Forest Laboratories’ (NYSE: FRX) longstanding global
partnerships and track record developing and marketing
pharmaceutical products in the United States have yielded its
well-established central nervous system and cardiovascular
franchises and innovations in anti-infective and respiratory,
gastrointestinal, and pain management medicine. The Company’s
pipeline, the most robust in its history, includes product
candidates in all stages of development across a wide range of
therapeutic areas. The Company is headquartered in New York, NY. To
learn more, visit www.FRX.com.
Except for the historical information contained herein, this
release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. These
statements involve a number of risks and uncertainties, including
the difficulty of predicting FDA approvals, the acceptance and
demand for new pharmaceutical products, the impact of competitive
products and pricing, the timely development and launch of new
products, and the risk factors listed from time to time in Forest
Laboratories' Annual Reports on Form 10-K, Quarterly Reports on
Form 10-Q, and any subsequent SEC filings. Forest assumes no
obligation to update forward looking statements contained in this
release to reflect new information or future events or
developments.
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Aug 2023 to Aug 2024